{{Drugbox
| IUPAC_name = (±)-1-(1,2-Diphenylethyl)piperidine
| image = Diphenidine.svg

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 36794-52-2
| ATC_prefix =
| ATC_suffix =
| PubChem = 206666
| ChemSpiderID      = 179031
| UNII = H8Q4VPL82Y

<!--Chemical data-->
| C=19 | H=23 | N=1
| molecular_weight = 265.39 g/mol
| melting_point = 210
| smiles            = c1ccc(cc1)CC(c2ccccc2)N3CCCCC3
| StdInChI          = 1S/C19H23N/c1-4-10-17(11-5-1)16-19(18-12-6-2-7-13-18)20-14-8-3-9-15-20/h1-2,4-7,10-13,19H,3,8-9,14-16H2
| StdInChIKey       = JQWJJJYHVHNXJH-UHFFFAOYSA-N
}}

'''Diphenidine''' ('''1,2-DEP''', '''DPD''', '''DND''') is a [[Dissociative drug|dissociative]] [[anesthesia|anesthetic]] that has been sold as a [[designer drug]].<ref name="Morris">{{cite journal | first1=H. | first2=J. | last1=Morris | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1620/abstract | title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs | date=July–August 2014 | last2=Wallach | journal=Drug Testing and Analysis | volume=6 | issue=7–8 | pages=614–632 | doi=10.1002/dta.1620 | pmid=24678061}}</ref><ref>{{cite journal|first1=Carina S. D.|last1=Wink|first2=Julian A.|last2=Michely|first3=Andrea|last3=Jacobsen-Bauer|first4=Josef|last4=Zapp|title=Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MSn, and LC-HR-MSn|url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1946/abstract|journal=Drug Testing and Analysis|date=1 January 2016|issn=1942-7611|pages=1005–1014|doi=10.1002/dta.1946|first5=Hans H.|last5=Maurer|pmid=26811026|volume=8}}</ref><ref>{{cite journal|first1=Anders|last1=Helander|first2=Olof|last2=Beck|first3=Matilda|last3=Bäckberg|title=Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine|url=http://www.tandfonline.com/doi/full/10.3109/15563650.2015.1033630|journal=Clinical Toxicology|date=28 May 2015|issn=1556-3650|pages=446–453|volume=53|issue=5|doi=10.3109/15563650.2015.1033630|pmid=25881797}}</ref> The synthesis of diphenidine was first reported in 1924, and employed a Bruylants reaction analogous to the one that would later be used to discover [[phencyclidine]] in 1956.<ref name="Morris"/> Shortly after the 2013 UK ban on [[arylcyclohexylamine]]s, diphenidine and the related compound [[methoxphenidine]] became available on the [[grey market]].<ref name="Morris"/> Anecdotal reports describe high doses of diphenidine producing "bizarre somatosensory phenomena and transient anterograde amnesia."<ref name="Morris"/> Diphenidine and related diarylethylamines have been studied in vitro as treatments for neurotoxic injury and are antagonists of the [[NMDA receptor]].<ref>{{cite web | url=https://www.surechembl.org/document/EP-0346791-B1/ | title=Patent EP 0346791 - 1,2-diarylethylamines for treatment of neurotoxic injury | via=SureChEMBL | publisher=G.D. Searle, LLC | date=6 April 1994 | author1=Nancy M. Gray | author2=Brian K. Cheng}}</ref><ref name="Berger">{{cite journal | first1=M. L. | last1=Berger | url=http://www.sciencedirect.com/science/article/pii/S0968089609002624 | title=NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds | date=May 2009 | last2=Schweifer | first2=A. | last3=Rebernik | first3=P. | last4=Hammerschmidt | first4=F. | journal=Bioorganic & Medicinal Chemistry | volume=17 | issue=9 | pages=3456–3462 | doi=10.1016/j.bmc.2009.03.025 | pmid=19345586}}</ref><ref name=Wallach/><ref>{{cite journal | title=Active NMDA glutamate receptors are expressed by mammalian osteoclasts | author1=Leon Espinosa | author2=Cécile Itzstein | author3=Hervé Cheynel | author4=Pierre D Delmas | author5=Chantal Chenu | journal=The Journal of Physiology | date=July 1999 | volume=518 | issue=1 | pages=47–53 | doi=10.1111/j.1469-7793.1999.0047r.x | pmid=10373688 | PMC=2269403}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/0165614793900055 | title=Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines | author1=Michael A. Rogawski | journal=Trends in Pharmacological Sciences | date=September 1993 | volume=14 | issue=9 | pages=325–331 | doi=10.1016/0165-6147(93)90005-5 | pmid=7504360}}</ref> In dogs diphenidine exhibits greater antitussive potency than [[codeine phosphate]].<ref name="Kasé">{{cite journal | author1=Yoshitoshi Kasé | url=http://pubs.acs.org/doi/abs/10.1021/jm00338a007 | title=Piperidino Groups in Antitussive Activity | date=March 1961 | author2=Tomokazu Yuizono | author3=Mieko Muto | journal=Journal of Medicinal Chemistry | volume=6 | issue=2 | pages=118–122 | doi=10.1021/jm00338a007 | pmid=14188779}}</ref><ref>{{cite journal|first1=P. M. B.|last1=Cahusac|first2=S. S.|last2=Senok|first3=I. S.|last3=Hitchcock|first4=P. G.|last4=Genever|title=Are unconventional NMDA receptors involved in slowly adapting type I mechanoreceptor responses?|url=http://www.sciencedirect.com/science/article/pii/S0306452205003143|journal=Neuroscience|date=May 2005|pages=763–773|volume=133|issue=3|via=ScienceDirect|doi=10.1016/j.neuroscience.2005.03.018|first5=K. I.|last5=Baumann|pmid=15908129}}</ref>

[[Electrophysiology|Electrophysiological]] analysis demonstrates that the amplitude of NMDA-mediated [[excitatory postsynaptic potential#Field EPSPs|fEPSPs]] are reduced by diphenidine and ketamine to a similar extent, with diphenidine displaying a slower onset of antagonism.<ref name="Wallach">{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1689/abstract | date=May 2015 | first1=J. | first10=N. | first11=S. | first2=P. | first3=G. | first5=J. | last6=Elliott | first6=S. | last1=Wallach | last10=Dempster | last11=Brandt | title=Preparation and characterization of the ‘research chemical’ diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers | last2=Kavanagh | last3=McLaughlin | last4=Morris | first4=N. | last5=Power | last7=Mercier | first7=M. | last8=Lodge | first8=D. | last9=Morris | first9=H. | journal=Drug Testing and Analysis | volume=7 | issue=5 | pages=358–367 | doi=10.1002/dta.1689 | pmid=25044512}}</ref> The two enantiomers of diphenidine differ greatly in their ability to block the NMDA receptor, with the more potent (S)-enantiomer possessing affinity forty times higher than the (R)-enantiomer.<ref name="Berger"/> Since diphenidine's introduction in 2013 vendors have stated the drug "acts on dopamine transport" yet no data concerning the action of diphenidine on the [[dopamine transporter]] was published until 2016.<ref name="Morris"/> Diphenidine's highest affinity is for the NMDA receptor, but it does display submicromolar affinity for the [[sigma-1 receptor|σ<sub>1</sub> receptor]], [[sigma-2 receptor|σ<sub>2</sub> receptor]] and [[dopamine transporter]].<ref name="WallachPLOS">{{cite journal|first1=Jason|last1=Wallach|first2=Heather|last2=Kang|first3=Tristan|last3=Colestock|first4=Hamilton|last4=Morris|title=Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues|journal=PLOS ONE|date=17 June 2016|issn=1932-6203|pages=e0157021|volume=11|issue=6|doi=10.1371/journal.pone.0157021|first5=Zuner A.|last5=Bortolotto|first6=Graham L.|last6=Collingridge|first7=David|last7=Lodge|first8=Adam L.|last8=Halberstadt|first9=Simon D.|last9=Brandt|first10=Adeboye|last10=Adejare|pmid=27314670|pmc=4912077}}</ref>

Since 2014 there have been several published reports of diphenidine being sold in combination with other research chemicals, particularly synthetic cannabinoids and stimulants in Japanese [[synthetic cannabis|herbal incense]] blends.<ref name="Wurita">{{cite journal | author1=Amin Wurita | url=https://link.springer.com/article/10.1007%2Fs11419-014-0240-y | title=A large amount of new designer drug diphenidine coexisting with a synthetic cannabinoid 5-fluoro-AB-PINACA found in a dubious herbal product | date=August 2014 | author2=Koutaro Hasegawa | author3=Kayoko Minakata | author4=Kanako Watanabe | author5=Osamu Suzuki | journal=Forensic Toxicology | volume=32 | issue=2 | pages=331–337 | doi=10.1007/s11419-014-0240-y}}</ref><ref name="Hasegawa">{{cite journal | author1=Koutaro Hasegawa | url=https://link.springer.com/article/10.1007%2Fs11419-014-0245-6 | title=Postmortem distribution of AB-CHMINACA, 5-fluoro-AMB, and diphenidine in body fluids and solid tissues in a fatal poisoning case: usefulness of adipose tissue for detection of the drugs in unchanged forms | date=January 2015 | author2=Amin Wurita | author3=Kayoko Minakata | author4=Kunio Gonmori | author5=Hideki Nozawa | author6=Itaru Yamagishi | author7=Kanako Watanabe | author8=Osamu Suzuki | journal=Forensic Toxicology | volume=33 | issue=1 | pages=45–53 | doi=10.1007/s11419-014-0245-6}}</ref><ref name="Uchiyama">{{cite journal | author1=Nahoko Uchiyama | author2=Yoshihiko Shimokawa | author3=Ruri Kikura-Hanajiri | author4=Yosuke Demizu | author5=Yukihiro Goda | author6=Takashi Hakamatsuka | title=A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N–OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products | journal=Forensic Toxicology | date=July 2015 | volume=33 | issue=2 | pages=244–259 | doi=10.1007/s11419-015-0268-7 | pmid=26257833 | PMC=4525202}}</ref> The first reported seizure concerned a Japanese product called "fragrance powder" containing diphenidine and [[benzylpiperazine]].<ref name="Minakata">{{cite journal | author1=Kayoko Minakata | url=https://link.springer.com/article/10.1007%2Fs11419-015-0273-x | title=Diphenidine and its metabolites in blood and urine analyzed by MALDI-Q-TOF mass spectrometry | date=July 2015 | author2=Itaru Yamagishi | author3=Hideki Nozawa | author4=Koutaro Hasegawa | author5=Amin Wurita | author6=Kunio Gonmori | author7=Masako Suzuki | author8=Kanako Watanabe | author9=Osamu Suzuki | journal=Forensic Toxicology | volume=33 | issue=2 | pages=402–408 | doi=10.1007/s11419-015-0273-x}}</ref> A [[synthetic cannabis|herbal incense]] sold in the [[Shizuoka Prefecture]] under the name "Aladdin (sic) Spacial Edition" was found to contain diphenidine and [[5F-AB-PINACA]] at concentrations of 289&nbsp;mg/g and 55.5&nbsp;mg/g, respectively.<ref name="Wurita"/> A product called ‘‘Herbal Incense. The Super Lemon’’ containing [[AB-CHMINACA]], [[5F-AMB]], and diphenidine was implicated in a fatal poisoning.<ref name="Hasegawa"/> Most recently diphenidine consumed in conjunction with three [[substituted cathinones]], three [[benzodiazepines]], and alcohol was implicated in a fatal ingestion of "bath salt" and "liquid aroma" products in Japan.<ref name="Kudo">{{cite journal | author1=Keiko Kudo | url=http://www.sciencedirect.com/science/article/pii/S1344622315000887 | title=A fatal case of poisoning related to new cathinone designer drugs, 4-methoxy PV8, PV9, and 4-methoxy PV9, and a dissociative agent, diphenidine | date=September 2015 | author2=Yosuke Usumoto | author3=Ruri Kikura-Hanajiri | author4=Naomi Sameshima | author5=Akiko Tsuji | author6=Noriaki Ikeda | journal=Legal Medicine | volume=17 | issue=5 | pages=421–426 | doi=10.1016/j.legalmed.2015.06.005 | pmid=26162997}}</ref>

In Canada, MT-45 and its analogues were made Schedule I controlled substances.<ref>{{cite journal | url=http://www.gazette.gc.ca/rp-pr/p2/2016/2016-06-01/html/sor-dors106-eng.php | title=Regulations Amending the Food and Drug Regulations (Parts G and J — Lefetamine, AH-7921, MT-45 and W-18) | author=Denis Arsenault | journal=Canada Gazette | date=1 June 2016 | volume=150 | issue=11 | publisher=Government of Canada}}</ref> Possession without legal authority can result in maximum seven years imprisonment. Further, [[Health Canada]] amended the ''Food and Drug Regulations'' in May, 2016 to classify DND as a restricted drug. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.

==See also==
* [[AD-1211]]
* [[Ephenidine]]
* [[Fluorolintane]]
* [[Lanicemine]]
* [[Lefetamine]]
* [[Methoxphenidine]] (MXP)
* [[MT-45]]
* [[Remacemide]]

==References==
{{Reflist|2}}

{{Hallucinogens}}
{{Ionotropic glutamate receptor modulators}}

[[Category:Designer drugs]]
[[Category:Dissociative drugs]]
[[Category:NMDA receptor antagonists]]
[[Category:Piperidines]]
[[Category:Diarylethylamines]]